Nascent Biotech Inc. Overview
Pro stress-test →Nascent Biotech is a phase 2 clinical-stage biotech company pioneering the development of human monoclonal antibodies for the treatment of various cancers. The company's lead candidate, Pritumumab (PTB), is a human monoclonal antibody that has progressed to Phase 2 clinical trials for the treatment of brain cancer.
Strategic Profile
Pro stress-test →The company specializes in developing human antibody products for cancer treatment, with Pritimumab achieving FDA orphan drug status for addressing rare forms of cancer. NBIO's clinical premise is to modulate the human body's natural immune response using monoclonal antibodies and cytokines that can be combined to maximize therapeutic effectiveness.
Competitive Landscape
Pro stress-test →Nascent Biotech competes in the monoclonal antibody cancer immunotherapy space against larger biotechnology firms developing similar checkpoint inhibitors and antibody-based therapeutics. Competitors include established biotech companies with greater resources, though Nascent's focus on naturally-derived human antibodies and combination immunotherapy approaches differentiate its platform. The company targets rare/orphan cancer indications with unmet medical needs.
Industry Context
Nascent Biotech Inc. operates in Monoclonal antibody cancer immunotherapy.
Key facts
Founded: 2014 · Headquarters: Burnsville, US · Employees: N/A · Revenue: $3M · Market cap: N/A